Sunshine Biopharma Inc. short interest in 2023
In 2023, Sunshine Biopharma Inc.'s disclosed short interest ran from 1.36% of shares outstanding on 13 Jan 2023 to 0.45% on 29 Dec 2023, a change of -0.91 percentage points. The year's high was 2.39% on 31 May 2023 and its low 0.23% on 15 Dec 2023, averaging 1.07% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.49 days on 28 Apr 2023. Full history: Sunshine Biopharma Inc..
Cite this page
By year: 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 1.36% (13 Jan 2023)
- End of year
- 0.45% (29 Dec 2023)
- Change
- -0.91 pp
- High
- 2.39% (31 May 2023)
- Low
- 0.23% (15 Dec 2023)
- Average
- 1.07%
- Highest days to cover
- 6.49 (28 Apr 2023)
- SEC filings marked
- 7
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 1.36% | 1.59 | |
| 31 Jan 2023 | 1.75% | 1.00 | |
| 15 Feb 2023 | 1.89% | 1.33 | |
| 28 Feb 2023 | 1.57% | 5.03 | |
| 15 Mar 2023 | 1.35% | 3.47 | |
| 31 Mar 2023 | 0.98% | 2.13 | |
| 14 Apr 2023 | 1.25% | 2.27 | 10-K filed |
| 28 Apr 2023 | 1.17% | 6.49 | |
| 31 May 2023 | 2.39% | 1.71 | 10-Q filed, results (8-K) |
| 15 Jun 2023 | 1.43% | 1.00 | |
| 30 Jun 2023 | 1.02% | 2.16 | |
| 14 Jul 2023 | 0.69% | 1.41 | |
| 31 Jul 2023 | 0.33% | 1.00 | |
| 15 Aug 2023 | 2.30% | 1.15 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 1.09% | 2.69 | |
| 15 Sep 2023 | 0.72% | 1.65 | |
| 29 Sep 2023 | 0.74% | 2.78 | |
| 13 Oct 2023 | 0.81% | 1.94 | |
| 31 Oct 2023 | 0.52% | 2.78 | |
| 15 Nov 2023 | 0.37% | 1.00 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 0.29% | 1.00 | |
| 15 Dec 2023 | 0.23% | 1.00 | |
| 29 Dec 2023 | 0.45% | 1.00 |
See also: Sunshine Biopharma Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.